Filing Details
- Accession Number:
- 0001181431-15-002198
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-02-09 21:13:04
- Reporting Period:
- 2015-02-06
- Filing Date:
- 2015-02-09
- Accepted Time:
- 2015-02-09 21:13:04
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1396814 | Pacira Pharmaceuticals Inc. | PCRX | Pharmaceutical Preparations (2834) | 510619477 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1383242 | S James Scibetta | C/O Pacira Pharmaceuticals, Inc. 5 Sylvan Way, Suite 300 Parsippany CO 07054 | Svp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-02-06 | 15,000 | $1.61 | 20,230 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-02-06 | 4,293 | $110.17 | 15,937 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-02-06 | 5,904 | $111.11 | 10,033 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-02-06 | 3,103 | $111.98 | 6,930 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-02-06 | 1,700 | $112.91 | 5,230 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2015-02-06 | 15,000 | $0.00 | 15,000 | $1.61 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
38,250 | 2020-09-02 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.58 to $110.57, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.59 to $111.58, inclusive.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.59 to $112.58, inclusive.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $112.63 to $113.17, inclusive.
- The option vested as to 50% of the options on September 2, 2010 and vests as to the remaining options in successive equal monthly installments for the subsequent 24 months. The options become exercisable, to the extent vested, from and after the issuer's initial public offering.
- Includes 230 shares of common stock acquired under the issuer's employee stock purchase plan in December 2014.